NASDAQ$PRAX
Praxis Precision Medicines I · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Praxis Precision Medicines reported financial results for the first quarter ended March 31, 2021.
Praxis Precision Medicines reported a net loss of $27.4 million for the first quarter of 2021. As of March 31, 2021, Praxis had $270.8 million in cash, cash equivalents and marketable securities.
- Expanded pipeline with new indications for PRAX-114 and PRAX-944
- PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21
- PRAX-114 Phase 2 trial for treatment of essential tremor to initiate in 2H21
- PRAX-944 Phase 2 trial for treatment of Parkinson’s disease to initiate in 1H22
Headline financials
Revenue & EPS history
Praxis · Revenue · Quarterly
$0
Revenue by segment
Praxis · $500K total across 1 segment · Q3 2023
- Collaboration Revenue$500K—100.0%
Forward guidance
Praxis plans to initiate multiple Phase 2 trials in the second half of 2021 and the first half of 2022.
Tailwinds
- Initiate PRAX-114 Phase 2 trial for PTSD in 2H21
- Initiate PRAX-114 Phase 2 trial for essential tremor in 2H21
- Initiate PRAX-944 Phase 2 trial for Parkinson’s disease in 1H22
- Expect topline results from PRAX-114 Phase 2/3 Aria Study for MDD in 1H22
- Initiate PRAX-114 Phase 2 Study for adjunctive treatment of MDD in 3Q21
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
-0.3%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-4.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+22.3%
Q2 2022
Best reaction
-40.6%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | -6.4% | -22.2% | |
| Q4 2025 | +0.5% | +4.2% | -9.3% | |
| Q3 2025 | -4.7% | -2.2% | +44.4% | |
| Q1 2025 | +0.2% | -3.5% | +16.3% | |
| Q4 2024 | -40.6% | -41.8% | -40.6% | |
| Q3 2024 | +3.6% | +16.6% | -4.0% | |
| Q2 2024 | -1.1% | +2.0% | +13.3% | |
| Q1 2024 | -5.9% | -6.9% | -15.8% | |
| Q4 2023 | +6.3% | +2.3% | -7.3% | |
| Q3 2023 | +1.4% | -0.6% | +21.6% | |
| Q2 2023 | +10.8% | +17.0% | +43.9% | |
| Q1 2023 | -2.8% | -1.9% | -7.7% | |
| Q4 2022 | -4.2% | -13.0% | -77.0% | |
| Q3 2022 | -12.5% | -11.2% | -13.3% | |
| Q2 2022 | +22.3% | +33.2% | -3.4% | |
| Q1 2022 | +14.0% | +28.1% | -77.7% | |
| Q4 2021 | -1.9% | -4.2% | -22.9% | |
| Q3 2021 | +2.4% | +2.0% | -17.1% | |
| Q2 2020 | +12.7% | +35.9% | +42.8% | |
| Q2 2021 | +12.7% | +35.9% | +42.8% | |
| Q1 2021 | -16.4% | -16.1% | -20.2% | |
| Q4 2020 | -6.8% | -11.5% | -34.0% | |
| Q3 2020 | +2.3% | +18.2% | +54.7% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro